3 Promising US Penny Stocks With Market Caps Under $80M

As 2024 concludes, the U.S. stock market has experienced a mix of highs and lows, with major indices posting strong annual gains despite a weak finish. In the current market landscape, penny stocks—often representing smaller or newer companies—continue to capture investor interest due to their potential for value and growth. While the term "penny stocks" may seem outdated, these investments can still offer compelling opportunities for those looking beyond large-cap names, especially when backed by solid financials and promising prospects.

Top 10 Penny Stocks In The United States

Name	Share Price	Market Cap	Financial Health Rating
BAB (OTCPK:BABB)	$0.77	$6.03M	★★★★★★
Inter & Co (NasdaqGS:INTR)	$4.22	$1.84B	★★★★☆☆
QuantaSing Group (NasdaqGM:QSG)	$3.08	$111.43M	★★★★★★
Kiora Pharmaceuticals (NasdaqCM:KPRX)	$3.30	$9.9M	★★★★★★
ZTEST Electronics (OTCPK:ZTST.F)	$0.29	$10.49M	★★★★★★
CBAK Energy Technology (NasdaqCM:CBAT)	$0.94	$97.13M	★★★★★☆
Imperial Petroleum (NasdaqCM:IMPP)	$3.01	$93.12M	★★★★★★
Golden Growers Cooperative (OTCPK:GGRO.U)	$4.50	$67.38M	★★★★★★
BTCS (NasdaqCM:BTCS)	$2.47	$43.38M	★★★★★★
Smith Micro Software (NasdaqCM:SMSI)	$1.31	$24.65M	★★★★★☆

Click here to see the full list of 735 stocks from our US Penny Stocks screener.

Let's review some notable picks from our screened stocks.

ESSA Pharma (NasdaqCM:EPIX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ESSA Pharma Inc. is a clinical-stage pharmaceutical company developing small molecule drugs for prostate cancer treatment, with a market cap of $79.90 million.

Operations: ESSA Pharma Inc. has not reported any revenue segments.

Market Cap: $79.9M

ESSA Pharma Inc., a clinical-stage pharmaceutical company, is currently pre-revenue and focuses on developing prostate cancer treatments. It remains debt-free with substantial short-term assets of US$127.6 million, covering both its short- and long-term liabilities. Despite a seasoned management team, ESSA has faced challenges including increased weekly volatility and unprofitability with growing losses over the past five years. Recent earnings reports showed a net loss of US$28.54 million for 2024, up from the previous year. Additionally, ESSA terminated its Phase 2 trial for masofaniten due to insufficient efficacy compared to standard treatment options.

• Get an in-depth perspective on ESSA Pharma's performance by reading our balance sheet health report here.
• Understand ESSA Pharma's earnings outlook by examining our growth report.

VerifyMe (NasdaqCM:VRME)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: VerifyMe, Inc., along with its subsidiaries, offers traceability and customer support services using software and process technology, with a market cap of $8.29 million.

Operations: The company's revenue is derived from two segments: Authentication, generating $0.53 million, and Precision Logistics, contributing $24.73 million.

Market Cap: $8.29M

VerifyMe, Inc. faces challenges with its Nasdaq listing due to a prolonged period of trading below US$1 per share, risking delisting if compliance is not regained by June 2025. Despite being unprofitable with increased losses over five years, the company maintains a strong cash position exceeding its debt and has sufficient runway for over three years. Recent earnings showed sales of US$16.55 million for the first nine months of 2024, with significant net losses reported. Shareholder dilution occurred last year alongside heightened stock volatility and an inexperienced management team averaging 1.3 years in tenure.

• Click to explore a detailed breakdown of our findings in VerifyMe's financial health report.
• Evaluate VerifyMe's prospects by accessing our earnings growth report.

Milestone Scientific (NYSEAM:MLSS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Milestone Scientific Inc. is a biomedical technology company that focuses on the patenting, design, development, and commercialization of injection technologies and devices for medical, dental, and cosmetic applications globally; it has a market cap of $72.21 million.

Operations: The company's revenue is primarily derived from its Dental segment, which accounts for $8.75 million, while the Medical segment contributes $0.13 million.

Market Cap: $72.21M

Milestone Scientific Inc., with a market cap of US$72.21 million, is currently unprofitable but has reduced losses over the past five years by 4% annually. The company remains debt-free and possesses sufficient cash runway for over a year, despite shareholder dilution and significant insider selling recently. Revenue primarily stems from its Dental segment, while the Medical segment contributes minimally. Recent developments include securing a Federal Supply Schedule contract for its CompuFlo Epidural System, enhancing opportunities within federal healthcare systems like the Department of Defense and Veterans Affairs. Leadership changes are underway as CEO Arjan Haverhals retires at year-end.

• Dive into the specifics of Milestone Scientific here with our thorough balance sheet health report.
• Gain insights into Milestone Scientific's outlook and expected performance with our report on the company's earnings estimates.

Seize The Opportunity

• Click this link to deep-dive into the 735 companies within our US Penny Stocks screener.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Jump on the AI train with fast growing tech companies forging a new era of innovation.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com